Clinical trials
Clinical High Risk clinical trials
Below are recruiting clinical high risk clinical trials, each written for real people, not researchers. We’re tracking 553 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06476132RecruitingPhase 2
Belumosudil for lung transplant patients at risk of chronic rejection
This trial tests whether the drug Belumosudil can help prevent chronic lung rejection in people who recently had a lung transplant and showed signs of early rejection. It may improve long-term lung health.
Los Angeles, CaliforniaAges 12 years+ - NCT06207799RecruitingPhase 2
Drug combo before and after transplant for high-risk myeloma
This trial tests a two-step approach for people with newly diagnosed, high-risk multiple myeloma who are eligible for a stem cell transplant. You'll get a drug called elranatamab before transplant to 'purge' the cancer, and then after transplant, you'll get maintenance therapy guided by how well your cancer is controlled. The goal is to see if this reduces the chance of the cancer coming back.
Houston, TexasAges 18–75 - NCT07763197Recruiting
Sample collection for bladder cancer research
This study is collecting blood, urine, and tissue samples from people with high-risk non-muscle invasive bladder cancer to help develop better tests for tracking the disease. By participating, you might help improve future monitoring and treatment decisions.
Austin, TexasAges 18 years+ - NCT06859801Recruiting
Bone pain study combining ablation and radiation
This study looks at combining two treatments for painful bone tumors that have spread from other cancers. It tests if using both treatments together provides better pain relief than either alone.
San Diego, CaliforniaAges 21 years+ - NCT07582172RecruitingPhase 2
Stem Cell Transplant for Hard-to-Treat Blood Cancers in Older Adults
This trial tests a new combination of radiation and chemotherapy to prepare your body for a stem cell transplant from a matched donor. It's designed for older patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that hasn't responded well to standard treatments.
Duarte, CaliforniaAges 18 years+ - NCT07773064Recruiting
Eye scan and blood test to predict heart disease risk
This study looks at whether images of the back of your eye and certain substances in your blood can help identify people at high risk for heart disease. If you're having tests for chest pain or other heart concerns, this research may help improve early detection.
Beijing, Beijing MunicipalityAges 18–100 - NCT07513116Recruiting
Intermittent fasting for people at high risk of pancreatic cancer
This study tests whether following an intermittent fasting schedule (eating only during certain hours) can help people at high risk for pancreatic cancer. The trial uses an app to track eating patterns and fasting times, aiming to see if this approach may reduce cancer risk.
Houston, TexasAges 18 years+ - NCT07061977RecruitingPhase 3
New cancer drug combo for advanced cervical cancer
This trial tests if giving the immunotherapy drug pembrolizumab before and after standard chemoradiation works better than the standard approach for people with high-risk cervical cancer that has spread locally.
Birmingham, AlabamaAges 18 years+ - NCT07000357RecruitingPhase 3
Study of AZD0780 to reduce heart attack and stroke risk
This trial tests a new medication, AZD0780, to see if it helps prevent major cardiovascular events like heart attacks or strokes in people who already have heart or blood vessel disease, or are at high risk for a first event. It might be a good fit if your cholesterol isn't well-controlled despite current treatments.
Athens, AlabamaAges 18 years+ - NCT06085664RecruitingPhase 1/Phase 2
Immunotherapy before prostate cancer surgery
This trial tests a new immunotherapy drug (REGN5678) given before surgery to men with high-risk prostate cancer that hasn't spread. The goal is to see if the drug can shrink or control the cancer before the prostate is removed.
Houston, TexasAges 18 years+ - NCT07779109Recruiting
Shorter radiation course for endometrial cancer after surgery
This study tests a shorter, more intense course of radiation therapy after surgery for endometrial cancer. It aims to see if it is safe and works as well as standard radiation, while possibly reducing treatment time.
Zaragoza, ZaragozaAges 18–110 - NCT07347990Recruiting
Iptacopan for high-risk TA-TMA after stem cell transplant
This trial tests a new oral medicine called iptacopan for people who have a serious blood vessel complication after a stem cell transplant (TA-TMA) that is not improving with usual treatments. The goal is to see if iptacopan can help stop the damage and improve recovery.
Hangzhou, ChinaAges 12 years+ - NCT07378930Recruiting
ULTRA-SAFE: More frequent monitoring after advanced polyps
This trial compares a new, more frequent surveillance schedule (yearly stool tests and colonoscopies every 2 years) to the standard schedule for people who have had advanced polyps removed. It aims to see if the extra testing helps prevent future colon cancer.
Taipei, TaipeiAges 40–75 - NCT07628283Recruiting
Telemedicine stroke prevention program for rural elderly adults
This study tests whether using telemedicine (remote health technology) combined with care at a local village clinic can better prevent strokes and manage stroke risk in older adults living in rural areas. Participants will receive ongoing health monitoring and support tailored to their stroke risk factors.
Suqian, JiangsuAges 65 years+ - NCT07743580RecruitingPhase 3
Secutrelvir for covid-19 patients at high risk
This trial tests a new antiviral pill, secutrelvir, for people with mild to moderate covid-19 who are at higher risk of getting seriously ill. It aims to see if the drug can prevent hospitalization or severe disease.
Coral Gables, FloridaAges 12 years+ - NCT07787429RecruitingPhase 2
Comparing two treatments for high-risk bone cancer
This study tests two treatments for high-risk osteosarcoma (a bone cancer). It compares mifamurtide plus standard treatment versus sorafenib plus standard treatment to see which is safer and more effective.
Warsaw, MazovianAges 5 months–30 years - NCT07324720Recruiting
Comparing ischemia vs plaque risk for high-risk artery disease
This trial compares two ways to decide which heart artery blockages need treatment: one looks at blood flow, the other at plaque buildup and risk. It's for people with high-risk blockages to see which approach leads to better outcomes.
Seoul, Main BuildingAges 19 years+ - NCT07784387Recruiting
Bladder cancer study in Portugal
This study looks at the characteristics and outcomes of people with high-risk non-muscle-invasive bladder cancer in Portugal. It aims to understand the disease better and could help improve future treatments.
LisbonAges 18 years+ - NCT07690852Recruiting
Environmental exposures and breast cancer risk study
This study looks at how environmental exposures might affect breast cancer risk. It includes women at average risk, high risk, or those diagnosed with breast cancer before age 50, as well as healthcare providers.
Duarte, CaliforniaAges 18 years+ - NCT07428993RecruitingPhase 2
CAR T-Cell Therapy for High-Risk Osteosarcoma
This trial tests a new type of cell therapy called B7-H3 CAR T cells for children and young adults with high-risk osteosarcoma that hasn't spread or worsened after standard chemotherapy. The treatment uses your own immune cells that are modified to attack a protein (B7-H3) found on cancer cells.
Memphis, TennesseeAges Up to 21 years - NCT07076485RecruitingPhase 2
Shorter radiation after surgery for node-positive breast cancer
This trial tests shorter radiation schedules for people with breast cancer that has spread to lymph nodes or is high-risk. It aims to find a shorter course of radiation that is just as effective after surgery.
Loveland, ColoradoAges 18 years+ - NCT06398457RecruitingEarly Phase 1
Darzalex Before Stem Cell Transplant for High-Risk Graft Failure
This trial tests giving a drug called Darzalex Faspro before the usual desensitization and a stem cell transplant for people at high risk of graft failure due to donor-specific antibodies. The goal is to prevent the transplant from failing.
Baltimore, MarylandAges 18 years+ - NCT07552805Recruiting
Home monitoring device after major digestive surgery
This study tests a wearable patch called Multisense that monitors your health at home after major gastrointestinal surgery. It's designed to catch problems early so you can stay safe and avoid returning to the hospital.
Nice, Alpes-MaritimesAges 18 years+ - NCT05946213RecruitingPhase 3
Shorter radiation treatment for high-risk prostate cancer
This trial tests whether a shorter course of radiation works as well as the usual longer course for people with high-risk prostate cancer. The goal is to keep cancer control while possibly reducing treatment time and inconvenience.
Birmingham, AlabamaAges 18 years+
Hear when a new Clinical High Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for clinical high risk?
- Yes. Clin2 currently lists 553 recruiting clinical high risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a clinical high risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a clinical high risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.